肠康饮对溃疡性结肠炎大鼠SOD和iNOS影响的实验研究
|
摘要
目的:观察肠康饮(CKY)作用于UC大鼠的疗效及其机制。
方法:将70只健康Wistar大鼠随机分成6组,A组:正常对照组10只、B组:模型对照组12只、C组:CKY低剂量组12只、D组:CKY中剂量组12只、E组:CKY高剂量组12只、F组:SASP对照组12只。A组注入0.25m10.9%生理盐水灌肠,其余5组注入100mg/kg TNBS加50%乙醇0.25ml混合试剂灌肠。造模后第二天,C、D、E组分别按CKY11g/kg、22g/kg及44g/kg体重灌胃,F组按0.5g/kg体重灌胃,A、B组给予蒸馏水按10ml/kg体重灌胃。每日一次,灌胃体积均为10mL/kg,连续21天后按DAI标准评分、结肠组织损伤大体形态学评分和病理组织学评分。测定结肠组织中超氧化物歧化酶(SOD)活性和诱导型一氧化氮合酶(iNOS)表达。
结果:大鼠DAI评分、结肠组织损伤大体形态学评分和病理组织学评分、肠组织SOD活性及iNOS表达,E组与B组比较有极显著性差异(P＜0.01);D、F组与B组比较有显著性差异(P＜0.05);B、C组与A组比较有极显著性差异(P＜0.01);D、F组与A组比较有显著性差异(P＜0.05)。
结论:CKY是治疗UC大鼠模型的有效药物。E组疗效较F组为优。CKY可能是通过增强肠组织中SOD活性和降低iNOS表达达到治疗目的。
Objective To find the effect and mechanism of CKY to the ulcerative colitis rat model.
Methods Totally 70 healthy Wistar rats were divided into 6 groups by random.Group A(10 rats):normal control group.Group B(12 rats):model control group.Group C(12 rats): CKY low dose group.Group D(12 rats):CKY moderate dose group.Group E(12 rats):CKY high dose group.Group F(12 rats):SASP control group group.The rats of Group A were made with 0.25mL of 0.9%normal saline enemal.The others groups were made with 100mg/kg TNBS plus 0.25mL mixing reagent.The second day after the rat model establishment,the administration by stomach of CKY as 11g/kg,22g/kg,44g/kg were performed to rats in Group C,D,E.The administration by stomach of CKY were performed as 11ml/kg once daily.The DAI standard score and morphology and pathohistology score of colon injury were performed after twenty one days.The activity of superoxide dismutase (SOD) and the expression of induced nitricoxide synthase(iNOS) in colon were determined.
Results Extreme significant difference(P＜0.01)were found between Group E and B on the DAI standard score and morphology and pathohistology score of colon injury and the activity of SOD and the expression of iNOS in colon.Significant difference(P＜0.05) were found among Group D,F,B.Extreme significant difference(P＜0.01) were found between Group B,C and A.Significant difference(P＜0.05) were found between Group D,F and A.
Conclusion CKY is an active drug to the ulcerative colitis rat model.The therapeutic effect in Group E is superior to that of Group F.The therapeutic mechanism of CKY may enhance the activity of SOD and decrease the expression of iNOS in colon.
方法:将70只健康Wistar大鼠随机分成6组,A组:正常对照组10只、B组:模型对照组12只、C组:CKY低剂量组12只、D组:CKY中剂量组12只、E组:CKY高剂量组12只、F组:SASP对照组12只。A组注入0.25m10.9%生理盐水灌肠,其余5组注入100mg/kg TNBS加50%乙醇0.25ml混合试剂灌肠。造模后第二天,C、D、E组分别按CKY11g/kg、22g/kg及44g/kg体重灌胃,F组按0.5g/kg体重灌胃,A、B组给予蒸馏水按10ml/kg体重灌胃。每日一次,灌胃体积均为10mL/kg,连续21天后按DAI标准评分、结肠组织损伤大体形态学评分和病理组织学评分。测定结肠组织中超氧化物歧化酶(SOD)活性和诱导型一氧化氮合酶(iNOS)表达。
结果:大鼠DAI评分、结肠组织损伤大体形态学评分和病理组织学评分、肠组织SOD活性及iNOS表达,E组与B组比较有极显著性差异(P＜0.01);D、F组与B组比较有显著性差异(P＜0.05);B、C组与A组比较有极显著性差异(P＜0.01);D、F组与A组比较有显著性差异(P＜0.05)。
结论:CKY是治疗UC大鼠模型的有效药物。E组疗效较F组为优。CKY可能是通过增强肠组织中SOD活性和降低iNOS表达达到治疗目的。
Objective To find the effect and mechanism of CKY to the ulcerative colitis rat model.
Methods Totally 70 healthy Wistar rats were divided into 6 groups by random.Group A(10 rats):normal control group.Group B(12 rats):model control group.Group C(12 rats): CKY low dose group.Group D(12 rats):CKY moderate dose group.Group E(12 rats):CKY high dose group.Group F(12 rats):SASP control group group.The rats of Group A were made with 0.25mL of 0.9%normal saline enemal.The others groups were made with 100mg/kg TNBS plus 0.25mL mixing reagent.The second day after the rat model establishment,the administration by stomach of CKY as 11g/kg,22g/kg,44g/kg were performed to rats in Group C,D,E.The administration by stomach of CKY were performed as 11ml/kg once daily.The DAI standard score and morphology and pathohistology score of colon injury were performed after twenty one days.The activity of superoxide dismutase (SOD) and the expression of induced nitricoxide synthase(iNOS) in colon were determined.
Results Extreme significant difference(P＜0.01)were found between Group E and B on the DAI standard score and morphology and pathohistology score of colon injury and the activity of SOD and the expression of iNOS in colon.Significant difference(P＜0.05) were found among Group D,F,B.Extreme significant difference(P＜0.01) were found between Group B,C and A.Significant difference(P＜0.05) were found between Group D,F and A.
Conclusion CKY is an active drug to the ulcerative colitis rat model.The therapeutic effect in Group E is superior to that of Group F.The therapeutic mechanism of CKY may enhance the activity of SOD and decrease the expression of iNOS in colon.
引文
[1]Eaden J,Abrams K,Ekbom A,et al.Colorectal cancer prevention in ulcerative colitis:a case-control study[J].Aliment pharmacol Ther,2000,14:145-153.
[2]杨小波,罗云坚.古代中医对溃疡性结肠炎相关认识的启示[J].新中医,2007,39(5):103-104.
[3]崔庆荣,邓沂,李金田,等.于己百教授诊治慢性溃疡性结肠炎的经验[J].中华中医药学刊,2007,25(6):1123-1125.
[4]张隐庵.黄帝内经灵枢集注[M].上海:上海科学技术出版社,1958.
[5]巢元方.诸病源候论[M].北京:人民卫生出版社,1995.
[6]严用和.重订严氏济生方[M].北京:人民卫生出版社,1980.
[7]张苏颖,李淑云.溃疡性结肠炎中医辩治浅析[J].山东中医杂志,2003,22(10):5797
[8]王立春,马鑫,胡强基.溃疡性结肠炎的病机及相关问题探讨[J].山东中医杂志,2001,20(4):195.
[9]韩涛,谭丹,张毅.中药复方治疗溃疡性结肠炎研究探要[J].中国实验方剂学杂志,2007,13(3):69-71.
[10]张会珍,刘建平.许占民教授治疗慢性非特异性溃疡性结肠炎临床经验颉要[J].新中医,2002,34(11):14.
[11]宋琛虹,孙玲,崔俊.中医药治疗溃疡性结肠炎临床分析[J].中华中医药学刊,2007,25(1):186-188.
[12]刘端勇,陈爱民,赵海梅,等.从毒探讨活动期溃疡性结肠炎的发病机制[J].中国中医基础医学杂志,2004,10(4):251-252.
[13]王希利,彭艳红,孙明祎,等.溃疡性结肠炎痰瘀病机要素探析[J].中华中医药学刊,2007,25(4):720-722.
[14]崔庆荣,邓沂,李金田,等.于己百教授诊治慢性溃疡性结肠炎的经验[J].中华中医药学刊,2007,25(6):1123-1125.
[15]任喜洁.中医药治疗溃疡性结肠炎的研究进展[J].中国中医基础医学杂志,2006,12(2):160-161.
[16]叶柏.溃疡性结肠炎证治管见[J].南京中医药大学学报,2005,21(4):266-268.
[17]王希利,彭艳红,孙明祎,等.中医对溃疡性结肠炎的病因认识[J].辽宁中医杂 志,2007,34(5):572-573.
[18]王希利,彭艳红,孙明祎.溃疡性结肠炎的中医藏象观[J].中国中医基础医学杂志,2007,13(5):338-339.
[19]王希利,彭艳红,孙明祎,等.溃疡性结肠炎以肺脾痰瘀论治研究[J].辽宁中医杂志,2007,34(6):747-748.
[20]陈治水,危北海,陈泽民.慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗效标准(试行方案)[J].中国中西医结合杂志,1994,14(4):239-240.
[21]中国中医药学会内科学会.临床中医内科学(下)[M].北京:北京出版社,1994:1807-1809.
[22]韩涛,谭丹,张毅,等.中药复方治疗溃疡性结肠炎研究探要[J].中国实验方剂学杂志,2007,13(3):69-71.
[23]司书凯.溃疡性结肠炎辨证治疗30例[J].辽宁中医学院学报,2005,7(6):592.
[24]安雪峰,赵继国,任茜.中医辨证分型治疗慢性结肠炎82例[J].四川中医,2005,23(9):63-64.
[25]周男华.钟一棠治疗溃疡性结肠炎的经验[J].浙江中医药大学学报,2007,31(3):2 81-282.
[26]李玉锋,王垂杰.王垂杰治疗溃疡性结肠炎经验[J].辽宁中医杂志,2006,33(6):655-656.
[27]李瑞东,李佃贵,李晓荟.消溃方治疗溃疡性结肠炎80例[J].山东中医杂志,2006,25(3):161.
[28]冯静克,周建舍.温通止利法治疗溃疡性结肠炎寒结证120例[J].江苏中医药,2005,26(8):24.
[29]陈良金.益脾清肠汤治疗慢性溃疡性结肠炎74例临床观察[J].时珍国医国药,2006,17(11):2285.
[30]连建学,刘卫华,董彩红,等.结肠安治疗活动期溃疡性结肠炎65例临床研究[J].四川中医,2005,23(12):42-44.
[31]张尚华,邵湘宁.肠炎康治疗慢性溃疡性结肠炎72例疗效观察[J].新中医,2005,37(11):32-33.
[32]谢传星.逐瘀清肠汤治疗溃疡性结肠炎78例[J].陕西中医,2005,26(12):1332-1333.
[33]郭四红,陈爱萍.中药灌肠治疗慢性溃疡性结肠炎43例疗效观察[J].河南中医,2005,25(9):42-43.
[34]毛善武,毛乐.“六味结肠胶囊”治疗溃疡性结肠炎38例分析[J].中华实用中西医杂志,2005,5(18):15.
[35]刘伟.肠可宁冲剂治疗溃疡性结肠炎疗效观察[J].辽宁中医杂志,2005,32(6):564.
[36]王虹,陈凯.溃结宁汤治疗溃疡性结肠炎65例[J].陕西中医,2005,26(9):914-915.
[37]金小晶,张文博,史肃玉,等.中药治疗慢性溃疡性结肠炎63例疗效观察[J].时珍国医国药,2005,16(11):1146-1147.
[38]施海.中药治疗慢性溃疡性结肠炎90例临研床研究[J].上海中医药杂志,2006,40(11):18-19.
[39]唐尚友,王捷虹,任海勇,等.白头翁汤加味治疗溃疡性结肠炎68例临床观察[J].中国中医基础医学杂志,2006,12(11):848-849.
[40]徐建峰.中西医结合治疗溃疡性结肠炎36例临床观察[J].四川中医,2005,23(5):56-57.
[41]吴婉珍.中西医结合治疗溃疡性结肠炎92例[J].时珍国医国药,2005,16(11):1191.
[42]李海,赵自星.中西医结合治疗溃疡性结肠炎临床研究[J].中国中西医结合消化杂志,2007,15(3):193-194.
[43]刘利华,彭澎,陈开娟,等.中西医结合治疗慢性溃疡性结肠炎临床观察[J].中华中医药学刊2007,25(3):633-634.
[44]郑刚.中西医结合治疗溃疡性结肠炎52例[J].山西中医,2007,23(3):33.
[45]张顺景,吕芳.苦参对大鼠溃疡性结肠炎中SOD、MDA表达的影响[J].包头医学院学报,2005,21(2):112-113.
[46]岳治国.昆明山海棠对大鼠溃疡性结肠炎细胞因子的影响[J].中国医学理论与实践,2006,16(5):633-636.
[47]周燕红,刘毅飞.银杏天宝对大鼠实验性溃疡性结肠炎IFN-γ、IL-4的影响[J].咸宁学院学报(医学版),2005,19(3):164-166.
[48]胡旭光,利红宇.痛泻要方对肝郁脾虚型溃疡性结肠炎动物模型的治疗作用[J].广东药学院学报,2004,20(1):40-41.
[49]陈欣童,吴启端,李翎,等.肠炎康对溃疡性结肠炎动物功效的实验研究[J].现代预防医学,2006,33(2):202-203.
[50]谷松,关庆增,岳志军,等.加昧四逆散对溃疡性结肠炎肝郁模型IL-1β及其mRNA 表达的影响[J].中国中医基础医学杂志,2006,12(1):24-25.
[51]连建学,刘洁,李洛平,等.结肠安胶囊对实验性溃疡性结肠炎大鼠IL-6、SOD及MDA 表达的影响[J].陕西中医,2006,27(2):240-241.
[52]要丽英,焦君良,李士军,等.解毒化瘀扶正中药对溃疡性结肠炎血清免疫学及SOD变化的影响[J].四川中医,2003,21(1):7-9.
[53]唐利文,莫新民.三黄丸对溃疡性结肠炎大鼠模型组织TNF-α、IL-6、IL-8的影响[J].中医药导报,2005,11(5):67-68.
[54]李薇.白头翁汤治疗大鼠溃疡性结肠炎的免疫机制探讨[J].甘肃中医,2004,17(6):39.
[55]王真权,谢力子,王爱华.芩柏颗粒剂干预溃疡性结肠炎大鼠可溶性白介素2受体和IgG的实验研究[J].中医药通报,2004,8(4):48-49.
[56]王献坤,等.肠安康胶囊对大鼠溃疡性结肠炎的治疗作用与机理探讨[J].北京中医药大学学报,2004,(4):31.
[57]权启镇.菊花煎灌肠对溃疡性结肠炎血黏附分子的影响[J].中国肛肠杂志,2003,20(7):8-10.
[58]周泠,刘卓志.雷公藤多甙栓对溃疡性结肠炎大鼠SOD和MPO的影响[J].医学动物防制,2006,22(6):403-405.
[59]张涛,谢建群.清肠栓对溃疡性结肠炎大鼠血清白介素影响的研究[J].辽宁中医药大学学报,2006,8(4):50-52.
[60]陈英群,马贵同,冯怡.清肠泡腾栓对溃疡性结肠炎模型大鼠肿瘤坏死因子-α及白细胞介素-13的影响[J].中国中西医结合消化杂志,2005,13(2):94-96.
[61]吴焕淦,刘慧荣,施茵,等.隔药灸对溃疡性结肠炎大鼠结肠IL-1β、IGF-1表达影响的研究[J].江西中医学院学报,2004,16(6):56-59.
[62]施征,马晓笕,吴焕淦,等.针灸调节大鼠溃疡性结肠炎结肠组织COX-2及IL-1β的研究[J].江西中医学院学报,2004,16(3):38-40.
[63]Farrell RJ,LaMont JT.Microbial factors in inflammatory bowel disease.Gastroenterol Clin North Am 2002,31:41-62.
[64]Danese S,Fiocehi C.Etiopathogenesis of inflammatory bowel diseases[J].World J Gastroenterol,2006,12(30):4807.
[65]Schreiber S.Experimental immunomodulatory therapy of inflammatory bowel disease.Netherl JMed 1998;53:24-31.
[66]Schreiber S.Raedler A,Stenson WF,et al.[J].Gastroenterol Clin North Am,,1992, 21:451-502.
[67]Podolsky DK.Inflammation bowel disease.NEngl Med2002;347:417-429.
[68]许昌泰,郭学刚.溃疡性结肠炎与免疫因素[J].世界感染杂志,2004。4(6):524.526.
[69]Monteleone G,Monteleone I,Fina D,et al.Interleukin-21 enhantes T-helper cell type I signaling and interferon-gamma production in Crohn's disease[J].Gastroenterology,2005,128(3):687-694.
[70]Gustot T,Lemmers A,Louis E,et al.Profile of soluble cytokine reoeptors in Crohn's disease[J].Gut,2005,54(4):488-495.
[71]Saniabadi AR,Hanai H.Suzuki Y,et al.Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system:an adjunct or an alternative to drug therapy[J]?J Clin Apher,2005,20(3):171-184.
[72]Mittal RD,Bid HK,Ghoshal UC.IL-1 receptor antagonist(IL-1Ra) gene polymorphismin patients with inflammatory bowel disease in India[J].Stand J Gastroenterol,2005,40(7):827-831.
[73]Raddatz D,Bockemuhl M,Ramadori G Quantitative measurement of cytokine mRNA in inflammatory bowel disease:relation to clinical and endoscopic activity and outcome[J].Eur J Gastroenterol Hepatol,2005,17(5):547-557.
[74]王献坤,侯家玉,邢建峰,等.肠安康胶囊对大鼠溃疡性结肠炎的治疗作用及机理探讨[J].北京中医药大学学报,2004,27(4):31.
[75]李军华,何小飞,于皆平.雷公藤多甙对溃疡性结肠炎大鼠模型的保护作用[J].现代中西医结合杂志,2003,12(12):1245.
[76]张文俊,李兆申,许国铭,等.细胞凋亡调控蛋白Bcl-2和Bax在溃疡性结肠炎表达中的研究[J].中华消化内镜杂志,2003,20(4):262.
[77]刘时光.炎症性肠病与细胞凋亡.国外医学·消化系统疾病分册,2001,10(2):120.
[78]Suzuki A,Sugimura K,Ohtsuka K,et al.Fas/Fax ligand expression and characateristics of primed CD45RO+T cell in the inflamed mucosa of ulcerative colitis[J].Scand J Gastroenterol 2001,35(22):1278.
[79]NeurathMF,Finotto S,Fuss I,BoirivantM Galle PR,StroberW.Regulation of T-cell apoptosis in inflammatory bowl disease:to die or not to die,that is the mucosal question.Trends lmmuno12001;22:21-26.
[80]Simon HU.Neutrophil apoptosis pathyaways and their modifications in inflammation[J].ImmunolRev,2003,193(1):101.
[81]Buttke TM,Sandstrom PA.Oxidative stress as a mediator Of apoptosis[J],Immunol Today,2001,15(1):7.
[82]Vainer B,Nielsen OH.Correlation between circulating soluble ICAM-1 and prednisolone-induced amelioration of ulcerative colitis[J].Stand J Gastroenterol,2003,38(3):283-287.
[83]Vainer B,Sorensen S,et al.Expression of ICAM-1 in colon epithelial cells:an ultrastructural study performed on in vivo and in vitro models.Virchows Arch.2003,443(6):774-781.
[84]Shusterman T,Sela S,Cohen H,et al.Reshef R.Effect of the antioxidant Mesna (2-mercaptoethane sulfonate) On experimental colitis[J].Dig Dis Sci,2003,48(6):1177-1185.
[85]Vowinkel T,Kalogeris Y J,Mori M,et al.Impact of dextran ulfate sodium load on the severity of inflammation in experimental colitis[J].Dig Dis Sci,2004,49(4):556-564.
[86]Dubuquoy L,Jansson EA,Deeb S,et al.Impaired expression of pemxisome proliferator-activated receptor g in ulcerative colitis[J].Gastroenterology,2003,124(5):1265-1276.
[87]Bassaganyau-Riera J,Reynolds K,Martino-Catt S,et al.Activation of PPARg and by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease[J].Ga-stroenterology,2004,127(3):777-791.
[88]Muijsers R B,Goa K L.A review of its therapeutic use in mild-tomoderate ulcerative colitis[J].Drugs,2002,62(11):1689-1705.
[89]Ardizzone S,Porto G B.Comparative tolerability of therapies for ulcerative colitis[J].Drug Saf,2002,25(8):561-582.
[90]李晓军,张晓峰,马贵同.大鼠实验性溃疡性结肠炎动物模型的复制[J].河北医学,2003,9(6):528-530。
[91]徐叔云,卞如濂,陈修.中药药理研究方法学[M].北京:人民卫生出版社,1994,1103.
[92]Ho H.Luk,Joshua K.S.Ko,Hon S.Fung,et al.Delineation of the protective action of zinc sulfate on ulcerative colitis in rats. European Journal of Pharmacology, 2002, 443: 197.
[93] Mei Q, Yu JP, Xu JM, et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages [J]. Acta Pharmacol Sin, 2002, 23: 882.
[94] Okayasu I, Hatakeyama S, Yamada M, et al. Anovel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 1990, 98: 694.
[95] Arseneau KO, Pizarro TT, Cominelli F, et al. Discovering the cause of inflammatory bowel disease: lessons from animal models[J]. Current Opinion Gastroenterol, 2000, 16(4): 310.
[96] Rachmile witz D, Stamler JS, Bachwich D, et al. Enhanced Colonic Nitric Oxide Generation and Nitric Oxide Synthase Activity in Ulcerative Colitis and Crohn's Disease[J]. Gut, 1995, 36(5): 718-723.
[97] Kimura H, Hokari R, Miura S, et al. Increased Expression of an Inducible Isoform of Nitric Oxide Synthase and the Formation of Peroxynitrite in Colonic Mucose of Patients with Active Ulcerative Colitis[J].Gut, 1998, 42(1): 180-187.
[2]杨小波,罗云坚.古代中医对溃疡性结肠炎相关认识的启示[J].新中医,2007,39(5):103-104.
[3]崔庆荣,邓沂,李金田,等.于己百教授诊治慢性溃疡性结肠炎的经验[J].中华中医药学刊,2007,25(6):1123-1125.
[4]张隐庵.黄帝内经灵枢集注[M].上海:上海科学技术出版社,1958.
[5]巢元方.诸病源候论[M].北京:人民卫生出版社,1995.
[6]严用和.重订严氏济生方[M].北京:人民卫生出版社,1980.
[7]张苏颖,李淑云.溃疡性结肠炎中医辩治浅析[J].山东中医杂志,2003,22(10):5797
[8]王立春,马鑫,胡强基.溃疡性结肠炎的病机及相关问题探讨[J].山东中医杂志,2001,20(4):195.
[9]韩涛,谭丹,张毅.中药复方治疗溃疡性结肠炎研究探要[J].中国实验方剂学杂志,2007,13(3):69-71.
[10]张会珍,刘建平.许占民教授治疗慢性非特异性溃疡性结肠炎临床经验颉要[J].新中医,2002,34(11):14.
[11]宋琛虹,孙玲,崔俊.中医药治疗溃疡性结肠炎临床分析[J].中华中医药学刊,2007,25(1):186-188.
[12]刘端勇,陈爱民,赵海梅,等.从毒探讨活动期溃疡性结肠炎的发病机制[J].中国中医基础医学杂志,2004,10(4):251-252.
[13]王希利,彭艳红,孙明祎,等.溃疡性结肠炎痰瘀病机要素探析[J].中华中医药学刊,2007,25(4):720-722.
[14]崔庆荣,邓沂,李金田,等.于己百教授诊治慢性溃疡性结肠炎的经验[J].中华中医药学刊,2007,25(6):1123-1125.
[15]任喜洁.中医药治疗溃疡性结肠炎的研究进展[J].中国中医基础医学杂志,2006,12(2):160-161.
[16]叶柏.溃疡性结肠炎证治管见[J].南京中医药大学学报,2005,21(4):266-268.
[17]王希利,彭艳红,孙明祎,等.中医对溃疡性结肠炎的病因认识[J].辽宁中医杂 志,2007,34(5):572-573.
[18]王希利,彭艳红,孙明祎.溃疡性结肠炎的中医藏象观[J].中国中医基础医学杂志,2007,13(5):338-339.
[19]王希利,彭艳红,孙明祎,等.溃疡性结肠炎以肺脾痰瘀论治研究[J].辽宁中医杂志,2007,34(6):747-748.
[20]陈治水,危北海,陈泽民.慢性非特异性溃疡性结肠炎中西医结合诊断、辨证和疗效标准(试行方案)[J].中国中西医结合杂志,1994,14(4):239-240.
[21]中国中医药学会内科学会.临床中医内科学(下)[M].北京:北京出版社,1994:1807-1809.
[22]韩涛,谭丹,张毅,等.中药复方治疗溃疡性结肠炎研究探要[J].中国实验方剂学杂志,2007,13(3):69-71.
[23]司书凯.溃疡性结肠炎辨证治疗30例[J].辽宁中医学院学报,2005,7(6):592.
[24]安雪峰,赵继国,任茜.中医辨证分型治疗慢性结肠炎82例[J].四川中医,2005,23(9):63-64.
[25]周男华.钟一棠治疗溃疡性结肠炎的经验[J].浙江中医药大学学报,2007,31(3):2 81-282.
[26]李玉锋,王垂杰.王垂杰治疗溃疡性结肠炎经验[J].辽宁中医杂志,2006,33(6):655-656.
[27]李瑞东,李佃贵,李晓荟.消溃方治疗溃疡性结肠炎80例[J].山东中医杂志,2006,25(3):161.
[28]冯静克,周建舍.温通止利法治疗溃疡性结肠炎寒结证120例[J].江苏中医药,2005,26(8):24.
[29]陈良金.益脾清肠汤治疗慢性溃疡性结肠炎74例临床观察[J].时珍国医国药,2006,17(11):2285.
[30]连建学,刘卫华,董彩红,等.结肠安治疗活动期溃疡性结肠炎65例临床研究[J].四川中医,2005,23(12):42-44.
[31]张尚华,邵湘宁.肠炎康治疗慢性溃疡性结肠炎72例疗效观察[J].新中医,2005,37(11):32-33.
[32]谢传星.逐瘀清肠汤治疗溃疡性结肠炎78例[J].陕西中医,2005,26(12):1332-1333.
[33]郭四红,陈爱萍.中药灌肠治疗慢性溃疡性结肠炎43例疗效观察[J].河南中医,2005,25(9):42-43.
[34]毛善武,毛乐.“六味结肠胶囊”治疗溃疡性结肠炎38例分析[J].中华实用中西医杂志,2005,5(18):15.
[35]刘伟.肠可宁冲剂治疗溃疡性结肠炎疗效观察[J].辽宁中医杂志,2005,32(6):564.
[36]王虹,陈凯.溃结宁汤治疗溃疡性结肠炎65例[J].陕西中医,2005,26(9):914-915.
[37]金小晶,张文博,史肃玉,等.中药治疗慢性溃疡性结肠炎63例疗效观察[J].时珍国医国药,2005,16(11):1146-1147.
[38]施海.中药治疗慢性溃疡性结肠炎90例临研床研究[J].上海中医药杂志,2006,40(11):18-19.
[39]唐尚友,王捷虹,任海勇,等.白头翁汤加味治疗溃疡性结肠炎68例临床观察[J].中国中医基础医学杂志,2006,12(11):848-849.
[40]徐建峰.中西医结合治疗溃疡性结肠炎36例临床观察[J].四川中医,2005,23(5):56-57.
[41]吴婉珍.中西医结合治疗溃疡性结肠炎92例[J].时珍国医国药,2005,16(11):1191.
[42]李海,赵自星.中西医结合治疗溃疡性结肠炎临床研究[J].中国中西医结合消化杂志,2007,15(3):193-194.
[43]刘利华,彭澎,陈开娟,等.中西医结合治疗慢性溃疡性结肠炎临床观察[J].中华中医药学刊2007,25(3):633-634.
[44]郑刚.中西医结合治疗溃疡性结肠炎52例[J].山西中医,2007,23(3):33.
[45]张顺景,吕芳.苦参对大鼠溃疡性结肠炎中SOD、MDA表达的影响[J].包头医学院学报,2005,21(2):112-113.
[46]岳治国.昆明山海棠对大鼠溃疡性结肠炎细胞因子的影响[J].中国医学理论与实践,2006,16(5):633-636.
[47]周燕红,刘毅飞.银杏天宝对大鼠实验性溃疡性结肠炎IFN-γ、IL-4的影响[J].咸宁学院学报(医学版),2005,19(3):164-166.
[48]胡旭光,利红宇.痛泻要方对肝郁脾虚型溃疡性结肠炎动物模型的治疗作用[J].广东药学院学报,2004,20(1):40-41.
[49]陈欣童,吴启端,李翎,等.肠炎康对溃疡性结肠炎动物功效的实验研究[J].现代预防医学,2006,33(2):202-203.
[50]谷松,关庆增,岳志军,等.加昧四逆散对溃疡性结肠炎肝郁模型IL-1β及其mRNA 表达的影响[J].中国中医基础医学杂志,2006,12(1):24-25.
[51]连建学,刘洁,李洛平,等.结肠安胶囊对实验性溃疡性结肠炎大鼠IL-6、SOD及MDA 表达的影响[J].陕西中医,2006,27(2):240-241.
[52]要丽英,焦君良,李士军,等.解毒化瘀扶正中药对溃疡性结肠炎血清免疫学及SOD变化的影响[J].四川中医,2003,21(1):7-9.
[53]唐利文,莫新民.三黄丸对溃疡性结肠炎大鼠模型组织TNF-α、IL-6、IL-8的影响[J].中医药导报,2005,11(5):67-68.
[54]李薇.白头翁汤治疗大鼠溃疡性结肠炎的免疫机制探讨[J].甘肃中医,2004,17(6):39.
[55]王真权,谢力子,王爱华.芩柏颗粒剂干预溃疡性结肠炎大鼠可溶性白介素2受体和IgG的实验研究[J].中医药通报,2004,8(4):48-49.
[56]王献坤,等.肠安康胶囊对大鼠溃疡性结肠炎的治疗作用与机理探讨[J].北京中医药大学学报,2004,(4):31.
[57]权启镇.菊花煎灌肠对溃疡性结肠炎血黏附分子的影响[J].中国肛肠杂志,2003,20(7):8-10.
[58]周泠,刘卓志.雷公藤多甙栓对溃疡性结肠炎大鼠SOD和MPO的影响[J].医学动物防制,2006,22(6):403-405.
[59]张涛,谢建群.清肠栓对溃疡性结肠炎大鼠血清白介素影响的研究[J].辽宁中医药大学学报,2006,8(4):50-52.
[60]陈英群,马贵同,冯怡.清肠泡腾栓对溃疡性结肠炎模型大鼠肿瘤坏死因子-α及白细胞介素-13的影响[J].中国中西医结合消化杂志,2005,13(2):94-96.
[61]吴焕淦,刘慧荣,施茵,等.隔药灸对溃疡性结肠炎大鼠结肠IL-1β、IGF-1表达影响的研究[J].江西中医学院学报,2004,16(6):56-59.
[62]施征,马晓笕,吴焕淦,等.针灸调节大鼠溃疡性结肠炎结肠组织COX-2及IL-1β的研究[J].江西中医学院学报,2004,16(3):38-40.
[63]Farrell RJ,LaMont JT.Microbial factors in inflammatory bowel disease.Gastroenterol Clin North Am 2002,31:41-62.
[64]Danese S,Fiocehi C.Etiopathogenesis of inflammatory bowel diseases[J].World J Gastroenterol,2006,12(30):4807.
[65]Schreiber S.Experimental immunomodulatory therapy of inflammatory bowel disease.Netherl JMed 1998;53:24-31.
[66]Schreiber S.Raedler A,Stenson WF,et al.[J].Gastroenterol Clin North Am,,1992, 21:451-502.
[67]Podolsky DK.Inflammation bowel disease.NEngl Med2002;347:417-429.
[68]许昌泰,郭学刚.溃疡性结肠炎与免疫因素[J].世界感染杂志,2004。4(6):524.526.
[69]Monteleone G,Monteleone I,Fina D,et al.Interleukin-21 enhantes T-helper cell type I signaling and interferon-gamma production in Crohn's disease[J].Gastroenterology,2005,128(3):687-694.
[70]Gustot T,Lemmers A,Louis E,et al.Profile of soluble cytokine reoeptors in Crohn's disease[J].Gut,2005,54(4):488-495.
[71]Saniabadi AR,Hanai H.Suzuki Y,et al.Adacolumn for selective leukocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system:an adjunct or an alternative to drug therapy[J]?J Clin Apher,2005,20(3):171-184.
[72]Mittal RD,Bid HK,Ghoshal UC.IL-1 receptor antagonist(IL-1Ra) gene polymorphismin patients with inflammatory bowel disease in India[J].Stand J Gastroenterol,2005,40(7):827-831.
[73]Raddatz D,Bockemuhl M,Ramadori G Quantitative measurement of cytokine mRNA in inflammatory bowel disease:relation to clinical and endoscopic activity and outcome[J].Eur J Gastroenterol Hepatol,2005,17(5):547-557.
[74]王献坤,侯家玉,邢建峰,等.肠安康胶囊对大鼠溃疡性结肠炎的治疗作用及机理探讨[J].北京中医药大学学报,2004,27(4):31.
[75]李军华,何小飞,于皆平.雷公藤多甙对溃疡性结肠炎大鼠模型的保护作用[J].现代中西医结合杂志,2003,12(12):1245.
[76]张文俊,李兆申,许国铭,等.细胞凋亡调控蛋白Bcl-2和Bax在溃疡性结肠炎表达中的研究[J].中华消化内镜杂志,2003,20(4):262.
[77]刘时光.炎症性肠病与细胞凋亡.国外医学·消化系统疾病分册,2001,10(2):120.
[78]Suzuki A,Sugimura K,Ohtsuka K,et al.Fas/Fax ligand expression and characateristics of primed CD45RO+T cell in the inflamed mucosa of ulcerative colitis[J].Scand J Gastroenterol 2001,35(22):1278.
[79]NeurathMF,Finotto S,Fuss I,BoirivantM Galle PR,StroberW.Regulation of T-cell apoptosis in inflammatory bowl disease:to die or not to die,that is the mucosal question.Trends lmmuno12001;22:21-26.
[80]Simon HU.Neutrophil apoptosis pathyaways and their modifications in inflammation[J].ImmunolRev,2003,193(1):101.
[81]Buttke TM,Sandstrom PA.Oxidative stress as a mediator Of apoptosis[J],Immunol Today,2001,15(1):7.
[82]Vainer B,Nielsen OH.Correlation between circulating soluble ICAM-1 and prednisolone-induced amelioration of ulcerative colitis[J].Stand J Gastroenterol,2003,38(3):283-287.
[83]Vainer B,Sorensen S,et al.Expression of ICAM-1 in colon epithelial cells:an ultrastructural study performed on in vivo and in vitro models.Virchows Arch.2003,443(6):774-781.
[84]Shusterman T,Sela S,Cohen H,et al.Reshef R.Effect of the antioxidant Mesna (2-mercaptoethane sulfonate) On experimental colitis[J].Dig Dis Sci,2003,48(6):1177-1185.
[85]Vowinkel T,Kalogeris Y J,Mori M,et al.Impact of dextran ulfate sodium load on the severity of inflammation in experimental colitis[J].Dig Dis Sci,2004,49(4):556-564.
[86]Dubuquoy L,Jansson EA,Deeb S,et al.Impaired expression of pemxisome proliferator-activated receptor g in ulcerative colitis[J].Gastroenterology,2003,124(5):1265-1276.
[87]Bassaganyau-Riera J,Reynolds K,Martino-Catt S,et al.Activation of PPARg and by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease[J].Ga-stroenterology,2004,127(3):777-791.
[88]Muijsers R B,Goa K L.A review of its therapeutic use in mild-tomoderate ulcerative colitis[J].Drugs,2002,62(11):1689-1705.
[89]Ardizzone S,Porto G B.Comparative tolerability of therapies for ulcerative colitis[J].Drug Saf,2002,25(8):561-582.
[90]李晓军,张晓峰,马贵同.大鼠实验性溃疡性结肠炎动物模型的复制[J].河北医学,2003,9(6):528-530。
[91]徐叔云,卞如濂,陈修.中药药理研究方法学[M].北京:人民卫生出版社,1994,1103.
[92]Ho H.Luk,Joshua K.S.Ko,Hon S.Fung,et al.Delineation of the protective action of zinc sulfate on ulcerative colitis in rats. European Journal of Pharmacology, 2002, 443: 197.
[93] Mei Q, Yu JP, Xu JM, et al. Melatonin reduces colon immunological injury in rats by regulating activity of macrophages [J]. Acta Pharmacol Sin, 2002, 23: 882.
[94] Okayasu I, Hatakeyama S, Yamada M, et al. Anovel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology, 1990, 98: 694.
[95] Arseneau KO, Pizarro TT, Cominelli F, et al. Discovering the cause of inflammatory bowel disease: lessons from animal models[J]. Current Opinion Gastroenterol, 2000, 16(4): 310.
[96] Rachmile witz D, Stamler JS, Bachwich D, et al. Enhanced Colonic Nitric Oxide Generation and Nitric Oxide Synthase Activity in Ulcerative Colitis and Crohn's Disease[J]. Gut, 1995, 36(5): 718-723.
[97] Kimura H, Hokari R, Miura S, et al. Increased Expression of an Inducible Isoform of Nitric Oxide Synthase and the Formation of Peroxynitrite in Colonic Mucose of Patients with Active Ulcerative Colitis[J].Gut, 1998, 42(1): 180-187.